Uwe Koch

This inventor holds 19 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Lead Discovery Center Gmbh, Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Uwe Koch. Retrieved from https://idiyas.com/inventor/uwe-koch-tp7i64l3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 4)

% Patents Active = 68.4

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 65(Granted Patents)

Location History:

Albano Laziale, IT (2002)
Pomezia, IT (2006 - 2012)
Rome, IT (2006 - 2013)
Dortmund, DE (2015 - 2024)

Company Filing History:

7 out of 15

Lead Discovery Center Gmbh

patents

3 out of 47

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

patents

3 out of 1,334

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

4. 3 out of 2,405

Merck Sharp + Dohme Corp.

Bayer Intellectual Property Gmbh

patents

7. 1 out of 11

Instituto Di Ricerche Di Biologia Molecolare P. Angeletti

patents

8. 1 out of 4

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

patents

9. 1 out of 1

Istituto Di Ricerche Di Biologia Molecolare P. Angletti Spa

patent

10. 1 out of 8

Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.a.

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

CDK Inhibitors

Antiviral Agents

Cancer Treatment

Pyrazolo-Triazine

Coumarin Derivatives

Benzofuran Compounds

Heterocyclic Compounds

Polymerase Inhibitors

Indoles

Peptides

Dihydroxypyrimidine

Diketoacid Derivatives

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12606561 - Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors (2026-04-21),

2. 11858937 - Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors (2024-01-02),

3. 11111238 - Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer (2021-09-07),

4. 10703735 - 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer (2020-07-07),

5. 9573939 - Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases (2017-02-21),

6. 9567345 - Pharmaceutically active pyrazolo-triazine derivatives (2017-02-14),

7. 9549917 - Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases (2017-01-24),

8. 9265773 - Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases (2016-02-23),

9. 9226929 - Pharmaceutically active disubstituted triazine derivatives (2016-01-05),

10. 9096608 - Pharmaceutically active pyrazolo-triazine derivatives (2015-08-04),

11. 8999982 - Pharmaceutically active compounds as Axl inhibitors (2015-04-07),

12. 8354413 - Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) (2013-01-15),

13. 8314062 - Macrocyclic compounds as antiviral agents (2012-11-20),

14. 8101595 - Antiviral indoles (2012-01-24),

15. 7781422 - Antiviral indoles (2010-08-24),

Title: Innovations of Uwe Koch in Pharmaceutical Development

Introduction

Uwe Koch is a prolific inventor based in Dortmund, Germany, known for his significant contributions to pharmaceutical innovations. With a total of 18 patents to his name, Koch's work primarily focuses on developing new compounds for the treatment of various diseases, showcasing his dedication to advancing healthcare through innovation.

Latest Patents

Among Uwe Koch's recent patents are "Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors." This invention relates to derivatives that have potential applications in treating cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases, and infectious diseases. Additionally, he has developed "Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer." These novel coumarin derivatives serve as specific mitochondrial RNA polymerase inhibitors, marking an important leap forward in cancer treatment options.

Career Highlights

Throughout his career, Uwe Koch has been affiliated with notable companies, including Lead Discovery Center GmbH and Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. His work in these organizations has driven significant advancements in drug discovery and development, further highlighting his expertise in the field.

Collaborations

Uwe Koch has collaborated with distinguished colleagues, including Frank Narjes and Joerg Habermann. These partnerships have played a vital role in enhancing the quality and scope of his innovative research, contributing to the successful development of patents and pharmaceutical products.

Conclusion

Uwe Koch's contributions to the pharmaceutical industry exemplify the impact of dedicated inventors on society. His 18 patents reflect a commitment to improving health outcomes through innovative solutions. As he continues to work on groundbreaking inventions, Koch remains a key figure in the field of pharmaceutical research and development.

Profile summary based on public USPTO records.